BEN-MAIMON CAROLE has filed 6 insider transactions across 1 company since January 2024.
Most recent transaction: a grant/award of 100100 shares of Larimar Therapeutics, Inc. ($LRMR) on January 26, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 26, 2026 | Larimar Therapeutics, Inc. | $LRMR | BEN-MAIMON CAROLE | President and CEO | A | Common Stock | 100100 | $0.00 | 524,054.0000 | 85,590,392 | 23.61% | 0.12% |
| Jan. 26, 2026 | Larimar Therapeutics, Inc. | $LRMR | BEN-MAIMON CAROLE | President and CEO | A | Stock Option (Right to Buy) | 600600 | $0.00 | 600,600.0000 | 85,590,392 | 9999.99% | 0.70% |
| Jan. 22, 2025 | Larimar Therapeutics, Inc. | $LRMR | BEN-MAIMON CAROLE | President and CEO | A | Common Stock | 91000 | $0.00 | 423,954.0000 | 63,815,065 | 27.33% | 0.14% |
| Jan. 22, 2025 | Larimar Therapeutics, Inc. | $LRMR | BEN-MAIMON CAROLE | President and CEO | A | Stock Option (Right to Buy) | 546000 | $0.00 | 546,000.0000 | 63,815,065 | 9999.99% | 0.86% |
| Jan. 17, 2024 | Larimar Therapeutics, Inc. | $LRMR | BEN-MAIMON CAROLE | President and CEO | A | Common Stock | 66125 | $0.00 | 332,954.0000 | 43,909,069 | 24.78% | 0.15% |
| Jan. 17, 2024 | Larimar Therapeutics, Inc. | $LRMR | BEN-MAIMON CAROLE | President and CEO | A | Stock Option (Right to Buy) | 396750 | $0.00 | 396,750.0000 | 43,909,069 | 9999.99% | 0.90% |